Top Markets
#1 Status Status +15.88%
#2 Animecoin Animecoin +4.71%
#3 Hex Trust USD Hex Trust USD +4.51%
#4 MANTRA MANTRA +2.96%
#5 Raydium Raydium +2.65%
#6 Infinity Ground Infinity Ground +2.33%
#7 Holo Holo +2.24%
#8 OmniBridge Bridged Zcash (Solana) OmniBridge Bridged Zcash (Solana) +2.03%
#9 City Boy City Boy +1.97%
#10 Zcash Zcash +1.90%
Coin of the day
Status Status
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Rang in Aktien #171
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in... Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Aktienkurs
$451.59
Marktkapitalisierung
$114.70B
Veränderung (1 Tag)
-2.36%
Veränderung (1 Jahr)
-11.89%
Land
US
Handel Vertex Pharmaceuticals Incorporated (VRTX)

Kategorie

Healthcare
Umsatz von Vertex Pharmaceuticals Incorporated (VRTX)
Umsatz im Dec 2025 TTM: $12.04B
Laut den aktuellen Finanzberichten von Vertex Pharmaceuticals Incorporated beträgt der derzeitige Umsatz des Unternehmens (TTM) $12.04B. Im Jahr 2024 erzielte das Unternehmen einen Umsatz von $11.02B eine Steigerung gegenüber dem Umsatz im Jahr 2023, der $9.87B betrug. Der Umsatz ist der Gesamtbetrag, den ein Unternehmen durch den Verkauf von Waren oder Dienstleistungen erzielt. Im Gegensatz zum Gewinn werden keine Ausgaben abgezogen.
Umsatzverlauf für Vertex Pharmaceuticals Incorporated von 2000 bis 2026
Umsatz am Ende jedes Jahres
Jahr Umsatz ändert
2026 (TTM) $12.04B 0.31%
2025 $12.00B 8.90%
2024 $11.02B 11.66%
2023 $9.87B 10.51%
2022 $8.93B 17.91%
2021 $7.57B 22.06%
2020 $6.21B 49.07%
2019 $4.16B 36.59%
2018 $3.05B 22.46%
2017 $2.49B 46.20%
2016 $1.70B 64.89%
2015 $1.03B 77.86%
2014 $580.42M -52.11%
2013 $1.21B -20.63%
2012 $1.53B 8.25%
2011 $1.41B 883.91%
2010 $143.37M 40.49%
2009 $102.05M -41.85%
2008 $175.50M -11.81%
2007 $199.01M -8.02%
2006 $216.36M 34.47%
2005 $160.89M 56.63%
2004 $102.72M 48.56%
2003 $69.14M -57.08%
2002 $161.09M -3.82%
2001 $167.49M 114.38%
2000 $78.13M 0.00%
Umsatz vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Umsatz Umsatzunterschied Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B 302.35%
DK
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B 19.14%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B -24.56%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B 30.38%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $5.49B -54.39%
NL